Abstract:Background: Epigenetic gene silencing is one of the major causes of carcinogenesis. Its widespread occurrence in cancer genome could inactivate many cellular pathways including DNA repair, cell cycle control, apoptosis, cell adherence, and detoxification. The abnormal promoter methylation might be a potential molecular marker for cancer management.Methods: For rapid identification of potential targets for aberrant methylation in gynecological cancers, methylation status of the CpG islands of 34 genes was determined using pooled DNA approach and methylation-specific PCR. Pooled DNA mixture from each cancer type (50 cervical cancers, 50 endometrial cancers and 50 ovarian cancers) was made to form three test samples. The corresponding normal DNA from the patients of each cancer type was also pooled to form the other three control samples. Methylated alleles detected in tumors, but not in normal controls, were indicative of aberrant methylation in tumors. Having identified potential markers, frequencies of methylation were further analyzed in individual samples. Markers identified are used to correlate with clinico-pathological data of tumors using chi(2) or Fisher's exact test.Results: APC and p16 were hypermethylated across the three cancers. MINT31 and PTEN were hypermethylated in cervical and ovarian cancers. Specific methylation was found in cervical cancer (including CDH1, DAPK, MGMT and MINT2), endometrial cancer (CASP8, CDH13, hMLH1 and p73), and ovarian cancer (BRCA1, p14, p15, RIZ1 and TMS1). The frequencies of occurrence of hypermethylation in 4 candidate genes in individual samples of each cancer type (DAPK, MGMT, p16 and PTEN in 127 cervical cancers; APC, CDH13, hMLH1 and p16 in 60 endometrial cancers; and BRCA1, p14, p16 and PTEN in 49 ovarian cancers) were examined for further confirmation. Incidence varied among different genes and in different cancer types ranging from the lowest 8.2% (PTEN in ovarian cancer) to the highest 56.7% (DAPK in cervical cancer). Aberrant methylation for some genes (BRCA1, DAPK, hMLH1, MGMT, p14, p16, and PTEN) was also associated with clinico-pathological data.Conclusion: Thus, differential methylation profiles occur in the three types of gynecologic cancer. Detection of methylation for critical loci is potentially useful as epigenetic markers in tumor classification. More studies using a much larger sample size are needed to define the potential role of DNA methylation as marker for cancer management.

Analysis of Dickkopf-1 promoter methylation status in human primary cervical squamous cell carcinoma

[DNA Methylation of ZIC1 and KLOTHO Gene Promoters in Colorectal Carcinomas and Its Clinicopathological Significance].

Promoter methylation analysis of DKK2 may be a potential biomarker for early detection of cervical cancer

Detection of DKK-1 gene methylation in exfoliated cells of cervical squamous cell carcinoma and its relationship with high risk HPV infection

Promoter hypermethylation analysis of host genes in cervical intraepithelial neoplasia and cervical cancers on histological cervical specimens

Application of DNA methylation detection in triage of women undergoing colposcopy

Methylation Status of the Long Control Region of Hpv 16 in Clinical Cervical Specimens

Clinical Significance of Methylation of E-cadherin and P14arf Gene Promoters in Skin Squamous Cell Carcinoma Tissues.

Elevated DKK1 Expression is an Independent Unfavorable Prognostic Indicator of Survival in Head and Neck Squamous Cell Carcinoma

Limited Role of Promoter Methylation of MGMT and C13ORF18 in Triage of Low-Grade Squamous Intraepithelial Lesion

The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer.

Detection of aberrant methylation of RARβ2, GSTP1 and DAPK gene in prostate cancer and its clinical significance

Differential DNA Methylation Profiles in Gynecological Cancers and Correlation with Clinico-Pathological Data

Gene Promoter Methylation Patterns Throughout the Process of Cervical Carcinogenesis

Analysis of Promoter Hypermethylation of Death-Asscciated Protein Kinase Gene in Blood from Non-Small Cell Lung Cancer Patients

Methylation Status of DLEC1 Promoter in Colorectal Cancer Patients and Its Clinical Relevance

Methylation in the promoter regions of WT1, NKX6-1 and DBC1 genes in cervical cancer tissues of Uygur women in Xinjiang

Population-Based Case-Control Study On Dapk1, Rar-Beta 2 And Mgmt Methylation In Liquid-Based Cytology

Novel Mechanism of Wnt Signalling Activation Mediated by DICKKOPF-1 Methylation in Pancreatic Cancer

Bioinformatics analysis of methylation in cervical adenocarcinoma in Xinjiang, China

Population-based case–control study on DAPK1, RAR-β2 and MGMT methylation in liquid-based cytology